Literature DB >> 17526747

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Katarina Radosevic1, Catharina W Wieland, Ariane Rodriguez, Gerrit Jan Weverling, Ratna Mintardjo, Gert Gillissen, Ronald Vogels, Yasir A W Skeiky, David M Hone, Jerald C Sadoff, Tom van der Poll, Menzo Havenga, Jaap Goudsmit.   

Abstract

There is an urgent need for an efficacious vaccine against tuberculosis (TB). Cellular immune responses are key to an effective protective response against TB. Recombinant adenovirus (rAd) vectors are especially suited to the induction of strong T-cell immunity and thus represent promising vaccine vehicles for the prevention of TB. We have previously reported on rAd vector serotype 35, the serotype of choice due to low preexisting immunity worldwide, which expresses a unique fusion protein of Mycobacterium tuberculosis antigens Ag85A, Ag85B, and TB10.4 (Ad35-TBS). Here, we demonstrate that Ad35-TBS confers protection against M. tuberculosis when administered to mice through either an intranasal or an intramuscular route. Histological evaluation of lung tissue corroborated the protection and, in addition, demonstrated differences between two mouse strains, with diffuse inflammation in BALB/c mice and distinct granuloma formation in C57BL/6 mice. Epitope mapping analysis in these mouse strains showed that the major T-cell epitopes are conserved in the artificial fusion protein, while three novel CD8 peptides were discovered. Using a defined set of T-cell epitopes, we reveal differences between the two mouse strains in the type of protective immune response, demonstrating that different antigen-specific gamma interferon (IFN-gamma)-producing T cells can provide protection against M. tuberculosis challenge. While in BALB/c (H-2(d)) mice, a dominant CD8 T-cell response was detected, in C57BL/6 (H-2(b)) mice, more balanced CD4/CD8 T-cell responses were observed, with a more pronounced CD4 response in the lungs. These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526747      PMCID: PMC1951991          DOI: 10.1128/IAI.00004-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay.

Authors:  T W Tobery; S Wang; X M Wang; M P Neeper; K U Jansen; W L McClements; M J Caulfield
Journal:  J Immunol Methods       Date:  2001-08-01       Impact factor: 2.303

3.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.

Authors:  A Tanghe; S D'Souza; V Rosseels; O Denis; T H Ottenhoff; W Dalemans; C Wheeler; K Huygen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens.

Authors:  R L Skjøt; T Oettinger; I Rosenkrands; P Ravn; I Brock; S Jacobsen; P Andersen
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

6.  Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family.

Authors:  Rikke Louise Vinther Skjøt; Inger Brock; Sandra M Arend; Martin E Munk; Michael Theisen; Tom H M Ottenhoff; Peter Andersen
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.

Authors:  Laleh Majlessi; Marie-Jésus Rojas; Priscille Brodin; Claude Leclerc
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

Authors:  F J Fallaux; A Bout; I van der Velde; D J van den Wollenberg; K M Hehir; J Keegan; C Auger; S J Cramer; H van Ormondt; A J van der Eb; D Valerio; R C Hoeben
Journal:  Hum Gene Ther       Date:  1998-09-01       Impact factor: 5.695

Review 9.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

Authors:  John W Shiver; Emilio A Emini
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

10.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Ling Xu; Zhi-Yong Yang; Mario Roederer; Richard A Koup; Peter B Jahrling; Gary J Nabel
Journal:  Nature       Date:  2003-08-07       Impact factor: 49.962

View more
  70 in total

1.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Genetic immunization in the lung induces potent local and systemic immune responses.

Authors:  Kaimei Song; Diane L Bolton; Chih-Jen Wei; Robert L Wilson; Jeremy V Camp; Saran Bao; Joseph J Mattapallil; Leonore A Herzenberg; Leonard A Herzenberg; Charla A Andrews; Jerald C Sadoff; Jaap Goudsmit; Maria Grazia Pau; Robert A Seder; Pamela A Kozlowski; Gary J Nabel; Mario Roederer; Srinivas S Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-06       Impact factor: 11.205

3.  MHC-restricted Ag85B-specific CD8+ T cells are enhanced by recombinant BCG prime and DNA boost immunization in mice.

Authors:  Shihoko Komine-Aizawa; Jiansheng Jiang; Satoru Mizuno; Satoshi Hayakawa; Kazuhiro Matsuo; Lisa F Boyd; David H Margulies; Mitsuo Honda
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

4.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

5.  A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Authors:  M Tameris; D A Hokey; V Nduba; J Sacarlal; F Laher; G Kiringa; K Gondo; E M Lazarus; G E Gray; S Nachman; H Mahomed; K Downing; B Abel; T J Scriba; J B McClain; M G Pau; J Hendriks; V Dheenadhayalan; S Ishmukhamedov; A K K Luabeya; H Geldenhuys; B Shepherd; G Blatner; V Cardenas; R Walker; W A Hanekom; J Sadoff; M Douoguih; L Barker; M Hatherill
Journal:  Vaccine       Date:  2015-04-28       Impact factor: 3.641

6.  Recombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge.

Authors:  S C Esparza-González; A Troy; J Troudt; M J Loera-Arias; J Villatoro-Hernández; E Torres-López; J Ancer-Rodríguez; Y Gutiérrez-Puente; G Muñoz-Maldonado; O Saucedo-Cárdenas; R Montes-de-Oca-Luna; A Izzo
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

Review 7.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

8.  A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection.

Authors:  Hongmei Kong; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

9.  Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses.

Authors:  Rebecca Axelsson-Robertson; Frank Weichold; Donata Sizemore; Markus Wulf; Yasir A W Skeiky; Jerry Sadoff; Markus J Maeurer
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

Review 10.  Recent advances in the development of vaccines for tuberculosis.

Authors:  Mohamed Jawed Ahsan
Journal:  Ther Adv Vaccines       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.